-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Mineralys Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q3 2025.
- Mineralys Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$36.9M, a 34.5% increase year-over-year.
- Mineralys Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$171M, a 11.8% decline year-over-year.
- Mineralys Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$178M, a 147% decline from 2023.
- Mineralys Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$71.9M, a 141% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)